RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1

ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial

[Read more…]

Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024

Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to up to Approximately $400 Million Annually

[Read more…]

• $250 million (USD) plant will help produce transformational cell and gene therapies on a global scale

• Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials

• New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines

• 100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network

[Read more…]

• BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania

• BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost

• Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital

[Read more…]